A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus
2011

Efficacy and Safety of Neramexane for Tinnitus

Sample size: 431 publication 10 minutes Evidence: moderate

Author Information

Author(s): Suckfüll Markus, Althaus Michael, Ellers-Lenz Barbara, Gebauer Alexander, Görtelmeyer Roman, Jastreboff Pawel J, Moebius Hans J, Rosenberg Tanja, Russ Hermann, Wirth Yvonne, Krueger Hagen

Primary Institution: University of Munich

Hypothesis

Does neramexane improve symptoms in patients with moderate to severe subjective tinnitus?

Conclusion

Neramexane treatment is safe and shows a trend towards improvement in tinnitus symptoms, particularly at higher doses.

Supporting Evidence

  • The 50 mg/d neramexane group showed significant improvement in tinnitus annoyance and impact on life.
  • Patients treated with neramexane experienced a trend towards reduced tinnitus severity compared to placebo.
  • Dizziness was the most common side effect, increasing with higher doses of neramexane.
  • Secondary efficacy variables supported the trend of improvement in the 50 mg/d group.

Takeaway

This study tested a new medicine called neramexane to see if it helps people with ringing in their ears. It seems to help a little, especially at higher doses.

Methodology

The study was a randomized, double-blind, placebo-controlled trial with 431 patients receiving either neramexane or placebo for 16 weeks.

Potential Biases

Potential bias due to the involvement of employees from the sponsoring pharmaceutical company.

Limitations

The primary efficacy analysis did not show statistical significance at the pre-defined endpoint, and the study was limited to a specific patient demographic.

Participant Demographics

Patients aged 18 to 65, predominantly male and Caucasian, with moderate to severe tinnitus.

Statistical Information

P-Value

p<0.05 for secondary efficacy variables in the 50 mg/d group

Statistical Significance

p=0.098 for 50 mg/d; p=0.289 for 75 mg/d

Digital Object Identifier (DOI)

10.1186/1472-6815-11-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication